Royalty Pharma Long-Term Investments 2019-2024 | RPRX
Royalty Pharma long-term investments from 2019 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
- Royalty Pharma long-term investments for the quarter ending December 31, 2024 were $1.260B, a 24.44% increase year-over-year.
- Royalty Pharma long-term investments for 2024 were $1.26B, a 24.44% increase from 2023.
- Royalty Pharma long-term investments for 2023 were $1.012B, a 37.6% increase from 2022.
- Royalty Pharma long-term investments for 2022 were $0.736B, a 19.1% decline from 2021.
| Royalty Pharma Annual Long-Term Investments (Millions of US $) |
|
|---|---|
| 2024 | $1,260 |
| 2023 | $1,012 |
| 2022 | $736 |
| 2021 | $910 |
| 2020 | $917 |
| 2019 | $678 |
| 2018 | $0 |
| Royalty Pharma Quarterly Long-Term Investments (Millions of US $) |
|
|---|---|
| 2024-12-31 | $1,260 |
| 2024-09-30 | $1,237 |
| 2024-06-30 | $1,160 |
| 2024-03-31 | $1,101 |
| 2023-12-31 | $1,012 |
| 2023-09-30 | $876 |
| 2023-06-30 | $871 |
| 2023-03-31 | $753 |
| 2022-12-31 | $736 |
| 2022-09-30 | $1,012 |
| 2022-06-30 | $780 |
| 2022-03-31 | $925 |
| 2021-12-31 | $910 |
| 2021-09-30 | $927 |
| 2021-06-30 | $852 |
| 2021-03-31 | $872 |
| 2020-12-31 | $917 |
| 2020-09-30 | $1,240 |
| 2020-06-30 | $1,085 |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2018-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Finance | FIN-MISC SVCS | $18.723B | $2.264B |
| Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. | |||